But some patients can present with what's known as an anaplastic thyroid carcinoma (ATC) -- a rare and very aggressive tumor ...

A new clinical trial highlights that spotting a genetic subtype of these ATC tumors can be key to designing treatment that ...

A new study shows overdiagnosis of thyroid cancer continuing despite efforts to curb screening in asymptomatic patients.

Clinical trials of single-agent targeted drugs have shown limited efficacy. In the only trial of single-agent immunotherapy ...

Noah S. Kalman, MD, MBA, highlighted advancements in thyroid cancer treatment, emphasizing personalized therapies, molecular ...

Healing is a journey best shared, as seen with Julia and her husband, Ian. Julia’s cancer first appeared as a nodule on her ...

Researchers from The University of Texas MD Anderson Cancer Center have demonstrated that anti-PD-L1 immunotherapy in ...

Katherine first faced cancer at just 16 when she consulted her doctor regarding back ache – which alarmingly turned out to be ...

"Papillary thyroid cancer is the most common type ... It often requires prompt intervention due to its aggressive nature,” adds Dr Bambarkar. Thyroid cancer can develop for several reasons ...

This is usually the most severe type, because it’s aggressive in spreading to other parts of the body. It’s also rare (about 2% of thyroid cancer cases) and the hardest to treat.

A clinical trial at MD Anderson Cancer Center reveals promising results for anaplastic thyroid carcinoma (ATC) patients.